1. Home
  2. EXAS vs FRT Comparison

EXAS vs FRT Comparison

Compare EXAS & FRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXAS
  • FRT
  • Stock Information
  • Founded
  • EXAS 1995
  • FRT 1962
  • Country
  • EXAS United States
  • FRT United States
  • Employees
  • EXAS N/A
  • FRT N/A
  • Industry
  • EXAS Medical Specialities
  • FRT Real Estate Investment Trusts
  • Sector
  • EXAS Health Care
  • FRT Real Estate
  • Exchange
  • EXAS Nasdaq
  • FRT Nasdaq
  • Market Cap
  • EXAS 8.8B
  • FRT 9.0B
  • IPO Year
  • EXAS N/A
  • FRT N/A
  • Fundamental
  • Price
  • EXAS $43.28
  • FRT $97.44
  • Analyst Decision
  • EXAS Strong Buy
  • FRT Buy
  • Analyst Count
  • EXAS 18
  • FRT 14
  • Target Price
  • EXAS $70.59
  • FRT $117.93
  • AVG Volume (30 Days)
  • EXAS 2.0M
  • FRT 821.0K
  • Earning Date
  • EXAS 05-07-2025
  • FRT 05-01-2025
  • Dividend Yield
  • EXAS N/A
  • FRT 4.54%
  • EPS Growth
  • EXAS N/A
  • FRT 22.15
  • EPS
  • EXAS N/A
  • FRT 3.42
  • Revenue
  • EXAS $2,758,867,000.00
  • FRT $1,205,612,000.00
  • Revenue This Year
  • EXAS $13.02
  • FRT $5.26
  • Revenue Next Year
  • EXAS $13.02
  • FRT $5.44
  • P/E Ratio
  • EXAS N/A
  • FRT $28.34
  • Revenue Growth
  • EXAS 10.37
  • FRT 6.13
  • 52 Week Low
  • EXAS $40.62
  • FRT $94.58
  • 52 Week High
  • EXAS $79.62
  • FRT $118.34
  • Technical
  • Relative Strength Index (RSI)
  • EXAS 37.18
  • FRT 41.50
  • Support Level
  • EXAS $44.00
  • FRT $95.73
  • Resistance Level
  • EXAS $47.23
  • FRT $98.75
  • Average True Range (ATR)
  • EXAS 1.57
  • FRT 2.02
  • MACD
  • EXAS 0.09
  • FRT 0.29
  • Stochastic Oscillator
  • EXAS 23.60
  • FRT 66.09

About EXAS Exact Sciences Corporation

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.

About FRT Federal Realty Investment Trust

Federal Realty Investment Trust is a shopping center-focused retail real estate investment trust that owns high-quality properties in eight of the largest metropolitan markets. Its portfolio includes an interest in 102 properties, which includes 26.8 million square feet of retail space and over 3,100 multifamily units. Federal's retail portfolio includes grocery-anchored centers, superregional centers, power centers, and mixed-use urban centers. Federal Realty has focused on owning assets in highly desirable areas with significant growth, and as a result, the average population density and average median household income are higher for its portfolio than for any other retail REIT.

Share on Social Networks: